This subtype is associated with a lower mutational burden compared to other melanoma types, which can complicate treatment strategies, as TWT melanomas often do not respond well to targeted therapies that are effective in BRAF or NRAS mutant melanomas. This evidence concerns the gene BRAF and melanoma.